CD4 and melanoma: Using blood samples from melanoma patients who had previously been vaccinated with a 6MHP vaccine on the Mel41 trial and had developed a robust CD4+ T cell immune response to the TSY antigen[39], we analyzed lymphocyte viability and CD4+ T cell proliferation to the TSY nano-formulations ex vivo.